Published in N Engl J Med on October 19, 1989
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis. Proc Natl Acad Sci U S A (1990) 2.14
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest (1991) 1.64
Jaundice at 14 days of age: exclude biliary atresia. Arch Dis Child (1991) 1.61
Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch Dis Child (1993) 1.36
Light-regulated, tissue-specific immunophilins in a higher plant. Proc Natl Acad Sci U S A (1994) 1.24
Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg (1992) 1.18
Prospective study of the quality of life in patients assessed for liver transplantation: outcome in transplanted and not transplanted groups. J R Soc Med (1995) 1.15
The elderly liver transplant recipient: a call for caution. Ann Surg (2001) 1.15
Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B. Proc Natl Acad Sci U S A (1990) 1.15
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. J Surg Oncol Suppl (1993) 0.95
Surgical management of portal hypertension. West J Med (1995) 0.95
The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93
Liver transplantation--challenges for the future. West J Med (1991) 0.92
Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A (1993) 0.91
Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg (2004) 0.90
Liver transplantation. Arch Dis Child (1992) 0.87
Liver transplantation. Experience with 100 cases. West J Med (1991) 0.86
Renal dysfunction associated with liver transplantation. Postgrad Med J (1995) 0.83
Fifty years of surgery for portal hypertension at the Cleveland Clinic Foundation. Lessons and prospects. Ann Surg (1995) 0.83
Contrast-enhanced ultrasound with SonoVue in the evaluation of postoperative complications in pediatric liver transplant recipients. J Ultrasound (2007) 0.81
Development of a bioartificial liver employing xenogeneic hepatocytes. Cytotechnology (1997) 0.80
Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg (1997) 0.80
Improving Donor Livers by Inhibiting TNF-α Production. Ochsner J (2010) 0.79
Pre- and post-transplant assessment of liver function in paediatric liver transplantation. Eur J Pediatr (1992) 0.79
The role of everolimus in liver transplantation. Clin Exp Gastroenterol (2014) 0.79
Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. Hepatology (1999) 0.78
EGF and TGF-beta1 gene expression in chronically rejecting small bowel transplants. Dig Dis Sci (1999) 0.78
Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. Transplant Proc (1991) 0.77
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 0.76
Aspects of liver transplant pathology with emphasis on rejection and its mechanisms. J Clin Pathol (1994) 0.75
Liver transplantation for alcoholic liver disease, viral hepatitis, and hepatic neoplasms. Transplant Proc (1991) 0.75
Anthony Cerami Award in Translational Medicine: A Journey in Science: The Birth of Organ Transplantation with Particular Reference to Alloengraftment Mechanisms. Mol Med (2015) 0.75
Mechanisms of tumor necrosis factor-alpha and interleukin-6 induction during human liver transplantation. Mediators Inflamm (1993) 0.75
Controversies in patient selection for liver transplantation. West J Med (1993) 0.75
Phosphoinositide hydrolysis mediated by H1 receptors in autoimmune myocarditis mice. Mediators Inflamm (1993) 0.75
Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol (2013) 0.75
Application of contrast-enhanced ultrasound after liver transplantation: Current status and perspectives. World J Gastroenterol (2016) 0.75
Portal hypertension--the surgical pendulum. West J Med (1995) 0.75
Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol (2015) 0.75
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. J Gastroenterol (2016) 0.75
Intrahepatic enhanced expression of beta2-microglobulin conformational epitope in acute liver allograft rejection: evidence of modulation by glucocorticoids. Dig Dis Sci (1998) 0.75
[Liver transplantation and pregnancy: 1994 perspectives]. Arch Gynecol Obstet (1994) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
Left hepatic trisegmentectomy. Surg Gynecol Obstet (1982) 2.16
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 1.98
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation (1985) 1.75
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70
Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth (1998) 1.67
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Cyclosporine A augments the regenerative response after partial hepatectomy in the rat. Transplant Proc (1988) 1.64
Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology (1999) 1.64
Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol (1986) 1.63
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet (1992) 1.61
Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant (2009) 1.59
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation (1989) 1.58
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53
Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52
Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology (1997) 1.52
Drug development and testing in relation to cell migration and chimerism. Transplant Proc (1993) 1.52
"Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant (2013) 1.52
The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci U S A (1985) 1.51
Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol (1988) 1.50
Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49
Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. Transplantation (1995) 1.45
Orthotopic liver transplantation for alcoholic cirrhosis. JAMA (1988) 1.45
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41
Recurrent hepatic allograft injury in erythropoietic protoporphyria. Transplantation (1996) 1.41
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38
Neurologic complications of FK 506. Transplant Proc (1991) 1.34
Donor dendritic cell repopulation in recipients after rat-to-mouse bone-marrow transplantation. Lancet (1992) 1.32
The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32
Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol (1990) 1.31
The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol (2000) 1.31
A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology (1989) 1.30
Canine total orthotopic small bowel transplantation under FK 506. Transplant Proc (1991) 1.29